IL12

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Tuesday, October 3, 2023
Well, Vaccine, Interim, KOL, PMID, Biotechnology, ICI, PDSB, Nivolumab, Head, Pembrolizumab, Survival, Infection, Clinical trial, OS, Cancer, Food and Drug Administration, Burtness, Squamous-cell carcinoma, Cetuximab, PFS, Neck, EDT, Doctor of Philosophy, ASCO, IL12, Investigational New Drug, MD, Patient, HNSCC, HPV, Webcast, Knowledge, PMCID, Recurrence, Data monitoring committee, FDA, IND, ORR, DMC, Food, Safety, Pharmaceutical industry, Birth control

Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival rate of less than 30% for approved ICI1.

Key Points: 
  • Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival rate of less than 30% for approved ICI1.
  • VERSATILE-002 is investigating two patient populations whose cancer has returned or spread – ICI naïve and ICI refractory.
  • The ICI naïve group had not responded to standard-of-care treatments but had not yet been treated with an ICI.
  • A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer.

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Retrieved on: 
Wednesday, July 26, 2023
KRYS, US Foods, DNA, Human, Research and development, Krystal, Immunology, Drug discovery, Clinical trial, Skin, National Cancer Institute, Suma, Research, Associate, Lung, IL12, ET, MD, Patient, Lymph, Division, Blood, Webcast, UPMC, Cytokine, FDA, IL2, Safety, Gene, Tumor microenvironment, IND, Food, Pharmaceutical industry, Vaccine, Medicine

The Company will host an investor conference call and webcast, Thursday, July 27, 2023, at 8:00 am ET, to discuss the KB707 program.

Key Points: 
  • The Company will host an investor conference call and webcast, Thursday, July 27, 2023, at 8:00 am ET, to discuss the KB707 program.
  • The presentation for the investor conference call is attached to the Company’s Form 8-K .
  • Two formulations of KB707 are in development, a solution formulation for transcutaneous injection and an inhaled (nebulized) formulation for lung delivery.
  • “We believe KB707 is a unique and highly differentiated drug candidate with the potential to unlock the capabilities of cytokine-based immunotherapy,” said Suma Krishnan, President of Research & Development at Krystal Biotech.

Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team to help Manage its Growing Clinical Pipeline

Retrieved on: 
Thursday, June 1, 2023
Trinket, Drug development, HER2, National Center for Advancing Translational Sciences, Dragonfly, Robin, Bristol Myers Squibb, Eli Lilly, IL12, Research and development, Translational medicine, AbbVie, EGFR, Daiichi Sankyo, Merck, BMS, Therapy, IND, Pharmaceutical industry, Research

WALTHAM, Mass., June 1, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., today announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.

Key Points: 
  • WALTHAM, Mass., June 1, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., today announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.
  • "Robin and David, who will run Translational Medicine and Clinical Development in Oncology, respectively, are fantastic additions to the Dragonfly team."
  • Including partnered assets, there are presently six total Dragonfly-developed drugs in clinical studies, worldwide.
  • "We are delighted that Robin and David have joined Dragonfly," said Dr. Joe.

Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team to help Manage its Growing Clinical Pipeline

Retrieved on: 
Thursday, June 1, 2023
Trinket, Drug development, HER2, National Center for Advancing Translational Sciences, Dragonfly, Robin, Bristol Myers Squibb, Eli Lilly, IL12, Research and development, Translational medicine, AbbVie, EGFR, Daiichi Sankyo, Merck, BMS, Therapy, IND, Pharmaceutical industry, Research

WALTHAM, Mass., June 1, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., today announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.

Key Points: 
  • WALTHAM, Mass., June 1, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., today announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.
  • "Robin and David, who will run Translational Medicine and Clinical Development in Oncology, respectively, are fantastic additions to the Dragonfly team."
  • Including partnered assets, there are presently six total Dragonfly-developed drugs in clinical studies, worldwide.
  • "We are delighted that Robin and David have joined Dragonfly," said Dr. Joe.

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Retrieved on: 
Friday, January 6, 2023
Immunotherapy, Trinket, Therapy, Research, IL12, Sclerosis, Patient, Bristol Myers Squibb, Degenerative disease, BMS, Hematological Cancer Research Investment and Education Act, Hematology, HER2, Senior, EGFR, Pharmaceutical industry, Neuroscience, Dragonfly

WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-in outside of oncology.

Key Points: 
  • Dragonfly to receive a $25 million payment and is eligible to receive potential future milestones and royalties on net sales.
  • WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.
  • "We are delighted that our research collaboration initiated with Dragonfly in July 2020 on multiple sclerosis and neuro-inflammation has rapidly produced novel TriNKET drug candidate molecules that may provide new treatment options for patients with neurological diseases" said Richard Hargreaves, Senior Vice President, Neuroscience, Bristol Myers Squibb.
  • "We believe this opt-in decision by Bristol Myers Squibb further validates our drug discovery platform," said Bill Haney, Dragonfly's CEO.

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Retrieved on: 
Friday, January 6, 2023
Immunotherapy, Trinket, Therapy, Research, IL12, Sclerosis, Patient, Bristol Myers Squibb, Degenerative disease, BMS, Hematological Cancer Research Investment and Education Act, Hematology, HER2, Senior, EGFR, Pharmaceutical industry, Neuroscience, Dragonfly

WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-in outside of oncology.

Key Points: 
  • Dragonfly to receive a $25 million payment and is eligible to receive potential future milestones and royalties on net sales.
  • WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.
  • "We are delighted that our research collaboration initiated with Dragonfly in July 2020 on multiple sclerosis and neuro-inflammation has rapidly produced novel TriNKET drug candidate molecules that may provide new treatment options for patients with neurological diseases" said Richard Hargreaves, Senior Vice President, Neuroscience, Bristol Myers Squibb.
  • "We believe this opt-in decision by Bristol Myers Squibb further validates our drug discovery platform," said Bill Haney, Dragonfly's CEO.

Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022

Retrieved on: 
Tuesday, May 17, 2022
Risk, Engineering, Company, IL2, Vertex Pharmaceuticals, TILS, Patient, Therapy, Cytokine, IL23, IFN, List of Farscape characters, Bristol Myers Squibb, IL12, FDA, Convention center, Biotechnology, Toxicity, Technology, Abstract (summary), LinkedIn, Twitter, Vaccine, Obsidian

CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022.

Key Points: 
  • Design elements such as membrane-tethering to reduce risk of systemic toxicity and engineering of protease sites for controlled shedding enable fit-for-purpose engineering and potential to regulate multiple cytokines.
  • Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.
  • Obsidian's proprietary cytoDRiVE technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules.
  • For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter .

Philogen Reports Full Year 2021 Results and Provides Corporate Update

Retrieved on: 
Friday, April 1, 2022
Chemical library, European Journal of Nuclear Medicine and Molecular Imaging, Disease, Blood, EDA, Glioblastoma, Cash Cash, Therapy, Ligand, Group, L19, Interleukin, ORR, Nuclear medicine, Initial public offering, Mouse, EDB, MGMT, Survival, Research, Glioma, Lomustine, Observation, Antigen, Neoplasm, IL12, Cancer, Tissue, TNF, European Journal, Inflammation, Google Images, Intellectual property, CRO, Molecular imaging, News, IL2, BST, Soft-tissue sarcoma, IPO, IL10, Patient, Partnership, Backhaus, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Vaccine, Jaden Philogene-Bidace, Pfizer, Fibronectin, Phase

In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.

Key Points: 
  • In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.
  • Siena (Italy), 1 April 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding the Companys full year 2021 results and recent corporate developments.
  • "We are excited for the great progress we have made following our listing on the Italian Stock Exchange in March 2021.
  • Philogen has a rich pipeline of late-stage clinical assets and continues to innovate by generating new prototypes, commented Prof. Dr. Dario Neri, Chief Executive Officer of Philogen.

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

Retrieved on: 
Tuesday, January 25, 2022
U.S. Securities and Exchange Commission, Multiple myeloma, TME, Cytokine, Head, Security (finance), Squamous cell carcinoma, Process control block, Patient, UCL, Chinese University of Hong Kong, Dry ice, IL4, GLOBE, EBV, Neoplasm, TGF, Lymphoma, Inflammation, Ovarian cancer, Clinical trial, Private Securities Litigation Reform Act, TNF, IL15, Time, IL10, Toxic epidermal necrolysis, Leukemia, CUHK, Breast cancer, Cell, University College London, Cancer, Immune system, NK, Safety, Cytokine release syndrome, Research, Memory, IL12, Disease, Company, CIML, History, Protein, IL2, Marketing, Survival, NPC, Incidence, Epstein–Barr virus infection, IL18, NASDAQ, Mortality, Natural killer cell, Vaccine, Pharmaceutical industry

We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.

Key Points: 
  • We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.
  • History of EBV infection (commonly known as mono) and genetic polymorphisms drive the incidence of the disease, said RJ Tesi, INmune Bios Chief Executive Officer.
  • This peer-reviewed grant and international collaboration targeting what has historically been a difficult to treat solid tumor validates the versatility of INKmune.
  • Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.